Clinical Trials on Metastatic Solid Tumors Characterized by HER2/Neu Expression in New Zealand

Total 139 results

QuantumLeap Healthcare Collaborative

Recruiting

PRE-I-SPY Phase I/Ib Oncology Platform Program (PRE-I-SPY-PI)

Solid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditions

United States
Novartis Pharmaceuticals

Completed

Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer (BOLERO-3)

Metastatic Breast Cancer | HER2/Neu Over-expressing Locally Advanced Breast Cancer

China, United States, France, Hungary, Turkey, Japan, Germany, Singapore, Italy, Poland, Spain, United Kingdom, Thailand, Israel, Australia, Belgium, Greece, Argentina, Czech Republic, Mexico, Slovakia
Relay Therapeutics, Inc.

Active, not recruiting

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Solid Tumor, Adult | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Unresectable Solid Tumor | PIK3CA Mutation

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Terminated

Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | HER2/Neu-positive Breast Cancer

United States
Bellicum Pharmaceuticals

Suspended

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Solid Tumor, Adult | HER-2 Gene Amplification | HER-2 Protein Overexpression

United States
Relay Therapeutics, Inc.

Recruiting

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Solid Tumor, Adult | HER2-negative Breast Cancer | Unresectable Solid Tumor | PIK3CA Mutation

United States, Spain, France, Italy
QSAM Therapeutics, Inc.

Recruiting

A Dose Finding Study to Treat Bone Tumor(s)

Bone Cancer | Solid Tumor | Bone Tumor | Metastatic Cancer to the Bone | Metastatic Tumor to the Bone

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | HER2-Positive Breast Carcinoma

United States
Millennium Pharmaceuticals, Inc.

Completed

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

Melanoma | Solid Tumor | Metastatic Melanoma | Neoplasm

United States, United Kingdom
CytomX Therapeutics

Terminated

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

Solid Tumor | Unresectable or Metastatic Melanoma

Korea, Republic of, United States, Netherlands, Spain, Australia
Amgen

Completed

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

Sarcoma | Lymphoma | Colorectal Cancer | Non-Small Cell Lung Cancer | Advanced Solid Tumors | Metastatic Cancer | Solid Tumors | Carcinoid | Locally Advanced

United States, Spain, Poland
Jazz Pharmaceuticals

Completed

Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors (EMERGE-201) (EMERGE-201)

Advanced Solid Tumor | Metastatic Solid Tumor | Urothelial Cancer | Poorly Differentiated Neuroendocrine Carcinomas | Homologous Recombination Deficient-Positive Malignancies Agnostic

United States
Turning Point Therapeutics, Inc.

Recruiting

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Lymphoma | Locally Advanced Solid Tumors | Metastatic Solid Tumors | Primary CNS Tumors

United States, Korea, Republic of, Spain, Singapore, Taiwan, Australia, Italy, Canada, France, Denmark, United Kingdom
Memorial Sloan Kettering Cancer Center

Completed

A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

Breast Cancer | Metastatic Breast Cancer | Breast Cancer Stage IV | Solid Carcinoma | HER2-negative Breast Cancer | MEK1 Gene Mutation | MEK2 Gene Mutation

United States
Ikena Oncology
Bristol-Myers Squibb

Completed

A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma

Neoplasms | Neoplasm Metastasis | Solid Tumor | Metastatic Cancer | Bladder Cancer | Advanced Solid Tumor | Advanced Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Solid Tumor, Adult | Bladder Disease | Solid Carcinoma | Neoplasm Malignant | Neoplasm, Bladder | Locally Advanced... and other conditions

United States
Amgen

Completed

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Cancer | Breast Cancer | Breast Neoplasms | Metastatic Cancer | Breast Tumors | Solid Tumors | Oncology | Tumors | Metastases | Locally Recurrent and Metastatic Breast Cancer

United States, Belgium, France
GeneQuantum Healthcare (Suzhou) Co., Ltd.

Recruiting

Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors

HER2-positive Breast Cancer | HER2-positive Biliary Tract Cancer | HER2-Positive Salivary Gland Carcinomas | HER2-Positive Advanced Solid Tumor

China, Australia, United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Withdrawn

Voxel Based Diffusion Tensor Imaging in Predicting Response in Patients With Brain Metastases Undergoing Whole Brain Radiation Therapy or Stereotactic Radiosurgery

Unspecified Adult Solid Tumor, Protocol Specific | Tumors Metastatic to Brain

United States
TyrNovo Ltd.

Active, not recruiting

A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer

Head and Neck Cancer | Squamous Cell Carcinoma of Head and Neck | Metastatic Solid Tumor | Colorectal Adenocarcinoma | Solid Tumor, Adult | Recurrent Solid Tumor

United States, Israel
I-Mab Biopharma Co. Ltd.

Recruiting

Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors

Gastric Cancer | Solid Tumor | Metastatic Cancer | Advanced Cancer | Esophageal Adenocarcinoma | Gastroesophageal Junction Carcinoma

United States, China
AstraZeneca
Daiichi Sankyo Co., Ltd.

Active, not recruiting

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (DPT02)

Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer | Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer

Belgium, United States, Poland, India, Taiwan, Thailand, Korea, Republic of, Czechia, Russian Federation, United Kingdom, Spain, Australia, Canada, Italy, Netherlands
IDEAYA Biosciences

Recruiting

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Colorectal Cancer | Metastatic Uveal Melanoma | Cutaneous Melanoma | Other Solid Tumors

United States, Australia, Canada
Anaveon AG

Recruiting

A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).

Advanced Solid Tumor | Metastatic Melanoma | Melanoma (Skin) | Cutaneous Melanoma | Adult Disease

United States, Spain, Germany, France, Italy
NanoCarrier Co., Ltd.

Unknown

Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma

Sarcoma | Soft Tissue Sarcoma | Solid Tumor | Metastatic Sarcoma

United States
Genentech, Inc.
Chugai Pharmaceutical Co.

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Gastric Cancer | Metastatic Solid Tumor | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma

Korea, Republic of, Spain, Japan, New Zealand, Australia, United States, Italy, Brazil
Nanobiotix

Recruiting

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Metastatic Renal Cell Carcinoma | Squamous Cell Carcinoma of Head and Neck | Radiotherapy | Immunotherapy | Microsatellite Instability-High Solid Malignant Tumour | Metastasis From Malignant Tumor of Liver | Metastasis From Malignant Tumor of Cervix | Metastasis From Malignant Melanoma of Skin (Disorder) and other conditions

United States
Novartis Pharmaceuticals

Completed

Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

Metastatic Renal Cell Carcinoma | Advanced Solid Tumors | Metastatic Breast Cancer

Spain, Belgium, Italy, France, United States, New Zealand, United Kingdom
Synta Pharmaceuticals Corp.

Completed

STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors

Lymphoma | Leukemia | Hematological Malignancies | Metastatic or Unresectable Solid Tumors

United States
Orinove, Inc.

Active, not recruiting

ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer

Metastatic Breast Cancer | Advanced Solid Tumor

United States
Pieris Pharmaceuticals, Inc.

Completed

PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Bladder Cancer | HER2-positive Solid Tumor

United States
Chinook Therapeutics, Inc. (formerly Aduro)
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Advanced/Metastatic Solid Tumors or Lymphomas

United States
Exicure, Inc.

Terminated

Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors

Advanced or Metastatic Solid Tumors | Advanced or Metastatic Merkel Cell Carcinoma | Advanced or Metastatic Cutaneous Squamous Cell Carcinoma | Advanced or Metastatic Melanoma | Advanced or Metastatic Head and Neck Squamous Cell Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Breast Carcinoma | HER2/Neu Negative | Breast Adenocarcinoma | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma

United States, South Africa
University of Michigan Rogel Cancer Center
Memorial Sloan Kettering Cancer Center; University of California, San Francisco

Active, not recruiting

Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations (IMPACT)

Solid Tumor | Metastatic Cancer | Metastatic Castration Resistant Prostate Cancer

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Terminated

Riluzole and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Unspecified Adult Solid Tumor, Protocol Specific | Metastatic Cancer

United States
Pieris Pharmaceuticals, Inc.

Completed

PRS-343 in HER2-Positive Solid Tumors

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Bladder Cancer | HER2-positive Solid Tumor

United States
Werewolf Therapeutics, Inc.

Recruiting

WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma | Advanced or Metastatic Solid Tumors

United States
Aposense Ltd.

Unknown

Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.

Solid Tumors | Brain Metastases

United States
Antengene Biologics Limited

Recruiting

A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas (PROBE)

Advanced Solid Tumor | Metastatic Solid Tumor | Mature B-cell Non-Hodgkin Lymphoma

United States, Australia
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

M8891 First in Human in Solid Tumors (M8891)

Metastatic Renal Cell Carcinoma | Advanced Solid Tumors

United States
Memorial Sloan Kettering Cancer Center

Completed

The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies

Lymphoma | Metastatic Solid Tumor | Myeloproliferative Neoplasms (MPN)

United States
Prelude Therapeutics

Recruiting

PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation

Advanced Solid Tumor | Metastatic Solid Tumor | Non-small Cell Lung Cancers | SMARCA4 Gene Mutation

United States, France, Spain, Singapore, Netherlands
Ann & Robert H Lurie Children's Hospital of Chicago
National Cancer Institute (NCI); Northwestern University

Completed

Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases

Unspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific | Lung Metastases | Recurrent Childhood Rhabdomyosarcoma | Recurrent Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Recurrent Wilms Tumor and Other Childhood Kidney Tumors | Previously... and other conditions

United States
BeiGene

Recruiting

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Advanced Breast Cancer | Metastatic Breast Cancer | Advanced Solid Tumor | Non-small Cell Lung Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer | Hormone-receptor-positive...

Australia, United States
NantCell, Inc.
Takeda

Terminated

QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas (GAMMA)

Cancer | Pancreatic Cancer | Advanced Solid Tumors | Metastatic Cancer | Bone Metastases | Solid Tumors | Pancreas Cancer | Adenocarcinoma of the Pancreas | Oncology | Cancer of Pancreas | Metastatic Pancreatic Cancer | Metastases | Cancer of the Pancreas | Advanced Malignancy | Oncology Patients | Endocrine Cancer

Italy, Spain, United Kingdom, Belgium, Canada, Denmark, Romania, United States, Germany, Netherlands, Korea, Republic of, Russian Federation, Australia, Austria, Lithuania, Portugal, Greece, Poland, Switzerland, Serbia, Bulgaria, ... and more
Turning Point Therapeutics, Inc.

Terminated

A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC

Non-Small Cell Lung Cancer | NSCLC | Non Small Cell Lung Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | ALK Gene Mutation

United States, Australia, Korea, Republic of
National Cancer Institute (NCI)

Active, not recruiting

Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor

United States
Novartis Pharmaceuticals

Completed

A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors

Advanced Solid Tumors | Recurrent or Refractory Medulloblastoma | Locally Advanced or Metastatic Basal Cell Carcinoma

United States, United Kingdom, Switzerland, Netherlands
Y-mAbs Therapeutics

Withdrawn

177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)

Solid Tumor, Adult | Leptomeningeal Metastasis

United States, United Kingdom
Bolt Biotherapeutics, Inc.
Bristol-Myers Squibb

Recruiting

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

HER2-positive Breast Cancer | HER2-positive Colorectal Cancer | HER2-positive Solid Tumors | HER2-positive Gastroesophageal Cancer | HER2-positive Endometrial Cancer

United States, Spain, France, Korea, Republic of, Italy

Clinical Trials on Metastatic Solid Tumors Characterized by HER2/Neu Expression in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations